Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Miranda Myersburton

Physician Assistant Sterling, VA Physician Assistant

NPI 1447905914 CMS profile 11386914

197 Heather Glen Rd, Sterling, VA 20165

Open in the dashboard

General payments

$8,473

375 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miranda Myersburton of Sterling, VA is reported in the CMS Open Payments database as having received $8,473 across 375 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,119 139
2024 General $2,603 101
2023 General $2,195 111
2022 General $556 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miranda Myersburton
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Miranda Myersburton were reported at $3,119. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Miranda Myersburton Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $556 $155 $48–$522 $149
2023 $2,195 $167 $52–$557 $160
2024 $2,603 $178 $55–$600 $164
2025 $3,119 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,782 73 payments
  2. Gilead Sciences, Inc. $1,393 47 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $747 46 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $629 28 payments
  5. Pfizer Inc. $447 20 payments
  6. Celgene Corporation $436 39 payments
  7. Ardelyx, Inc. $366 27 payments
  8. Janssen Biotech, Inc. $358 13 payments
  9. Madrigal Pharmaceuticals $321 17 payments
  10. Regeneron Healthcare Solutions, Inc. $239 11 payments
  11. Other $1,755 54 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $8,473 375 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $755 36 payments
  2. SKYRIZI Immunology $706 25 payments
  3. ZEPOSIA $607 39 payments
  4. ENTYVIO $561 25 payments
  5. XIFAXAN $517 21 payments
  6. VELSIPITY $401 18 payments
  7. LINZESS $386 22 payments
  8. IBSRELA $366 27 payments
  9. SKYRIZI Immunology $334 14 payments
  10. XELJANZ $299 13 payments
  11. Other $3,493 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

747

Median for Physician Assistant: 241

Drug cost

$222,788

Median for Physician Assistant: $4,110

Branded share of claims

32.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 11 $97,086
Linzess Linaclotide Brand 41 $58,094
Mesalamine Generic 14 $13,356
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 62 $10,662
Mesalamine Er Mesalamine Brand 19 $7,495
Dexlansoprazole Dr Dexlansoprazole Brand 17 $7,204
Ursodiol Generic 18 $5,753
Colesevelam Hcl Generic 14 $5,327
Cholestyramine Cholestyramine (With Sugar) Brand 23 $3,796
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 55 $2,854

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$16,296

Medicare's payments for the services billed

Medicare patients

190

Average age 76

Services billed

216

105 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 55%
Ischemic heart disease 33%
Diabetes 31%
COPD 18%
Atrial fibrillation 16%
Chronic kidney disease 16%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $260
$260 — —
RINVOQ
  • AbbVie, Inc. $211
$211 — —
STELARA
  • Janssen Biotech, Inc. $148
$148 — —
ZEPOSIA
  • Celgene Corporation $144
$144 — —
DIFICID
  • Merck Sharp & Dohme Corporation $119
$119 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

375 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record